While adalimumab and methotrexate are understood to have a synergistic effect, the MUSICA trial sought to evaluate the ideal dose of methotrexate needed in patients who receive combination therapy for rheumatoid arthritis.
Although methotrexate is recommended as first-line treatment for patients with moderate to severe rheumatoid arthritis (RA), those patients who do not have an adequate response to methotrexate alone may have an anti—tumor necrosis factor therapy, such as adalimumab, added to their treatment. While adalimumab and methotrexate are understood to have a synergistic effect, the MUSICA trial sought to evaluate the ideal dose of methotrexate needed in patients who receive combination therapy.
Reporting on their results in Rheumatology and Therapy, investigators explained that they assessed a reduced methotrexate dose of 7.5 mg per week versus a high dose of 20 mg of methotrexate per week in 309 patients who previously had received doses of at least 15 mg per week.
Although the primary endpoint of the MUSICA study—the mean 28-joint disease activity score based on C-reactive protein at week 24—was not met, patient-reported outcomes (PROs) were also recorded weekly to week 24. In total, 154 patients were randomized to the low dose plus adalimumab group and 155 patients to the high dose plus adalimumab group.
The researchers found the following concerning PROs:
The authors concluded that both high- and low-dose groups showed rapid, significant improvements in PROs from baseline to week 24, and for many of these PROs, these improvements were comparable at both doses.
Reference
Kaeley GS, MacCarter DK, Goyal JR, et al. Similar improvements in patient-reported outcomes among rheumatoid arthritis patients treated with two different doses of methotrexate in combination with adalimumab: results from the MUSICA trial [published online March 24, 2018]. Rheumatol Ther. doi: 10.1007/s40744-018-0105-7.
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.